KTN1-AS1: A Potential Drug Target and Biomarker (G100129075)

Target Name: KTN1-AS1

NCBI ID: G100129075

KTN1-AS1

Other Name(s): MYCLo-3 | C14orf33 | KTN1 antisense RNA 1

KTN1-AS1: A Potential Drug Target and Biomarker

KTN1-AS1, also known as KTN1, is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a key regulator of the cell cycle, and its dysfunction has been implicated in various diseases, including cancer, neurodegenerative diseases, and developmental disorders.

Recent studies have identified KTN1-AS1 as a potential drug target and biomarker for various diseases. Its unique structure and regulation by multiple intracellular signaling pathways make it an attractive target for small molecules.

KTN1-AS1 as a Drug Target

KTN1-AS1 has been identified as a potential drug target by its involvement in various cellular processes that are crucial for disease development. One of its key functions is to regulate the cell cycle, which is the process by which cells grow, divide, and repair themselves. Disruptions in the cell cycle can lead to the formation of cancerous cells, and KTN1-AS1 plays a critical role in regulating the cell cycle during the G1 phase.

Several studies have shown that KTN1-AS1 is involved in the regulation of the G1 phase, including the timing of the G1/S transition and the levels of cyclin D1 and p21. Activation of the G1/S transition is necessary for cell growth, and the levels of cyclin D1 and p21 are critical for regulating the G1/S transition.

In addition to its role in regulating the cell cycle, KTN1-AS1 has also been shown to play a role in cell survival and angiogenesis. Several studies have shown that KTN1-AS1 is involved in the regulation of cell survival by preventing the formation of apoptotic cells. It also plays a role in the regulation of angiogenesis, the process by which new blood vessels are formed.

KTN1-AS1 as a Biomarker

KTN1-AS1 has also been identified as a potential biomarker for various diseases. Its involvement in the regulation of the cell cycle and cell survival makes it an attractive target for biomarkers that can be used to diagnose and monitor disease.

Studies have shown that KTN1-AS1 is significantly elevated in various tissues of cancer patients, including breast, ovarian, and colorectal cancers. This suggests that KTN1-AS1 may be a useful biomarker for cancer diagnosis and monitoring.

In addition to its potential as a cancer biomarker, KTN1-AS1 has also been shown to be involved in the regulation of neurodegenerative diseases. Several studies have shown that KTN1-AS1 is involved in the regulation of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In conclusion, KTN1-AS1 is a protein that has been identified as a potential drug target and biomarker for various diseases. Its unique structure and regulation by multiple intracellular signaling pathways make it an attractive target for small molecules. Further research is needed to fully understand its role in disease and its potential as a biomarker.

Protein Name: KTN1 Antisense RNA 1

The "KTN1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KTN1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets